Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 11:20:00 2024-06-21 am EDT 5-day change 1st Jan Change
987.9 DKK -0.59% Intraday chart for Novo Nordisk A/S -0.31% +41.51%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar RE
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says RE
Novo Nordisk Confirms WHO Coordination Amid Fake Ozempic Batches MT
WHO Issues First Medical Product Notice Amid Reports of Counterfeit Batches of Novo Nordisk's Ozempic MT
WHO issues warnings on falsified diabetes and weight-loss drugs RE
Lilly files additional lawsuits over US sales of counterfeit Mounjaro RE
Food companies with Ozempic-friendly snacks and meals wade carefully into weight-loss waters RE
India's Biocon seeks partner to test generic Wegovy, Ozempic in China RE
NOVO NORDISK : Deutsche Bank remains its Buy rating ZD
Novo Nordisk Says Fires at Danish Facilities Seemingly Unconnected, Not Linked to Criminal Activity MT
Novo Nordisk says no sign of crime, links between fires at Denmark facilities RE
Novo Nordisk says no sign of crime, links between fires at Denmark facilities RE
Novo Nordisk Says Fire at Denmark Building Under Control MT
Novo Nordisk Office Near Copenhagen Headquarters Hit by Fire DJ
A weight loss ETF MT
Novo Nordisk to present 34 abstracts at ADA CF
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Novo Nordisk CEO to Testify on High Prices of Ozempic, Wegovy in US Senate Hearing MT
Weight-loss options for US youth are hard to come by RE
Novo Nordisk CEO Agrees to US Senate Committee Testimony to Address 'Outrageously High' Ozempic, Wegovy Prices MT
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy RE
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
Novo Nordisk: study results for hemophilia A CF
NOVO NORDISK : Deutsche Bank reiterates its Buy rating ZD
Second Chinese drugmaker seeks approval for Ozempic generic RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9 DKK
Average target price
934.3 DKK
Spread / Average Target
-5.43%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says